Oct 22, 2024 · ABRYSVO now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV immunization approved for pregnant individuals at 32 through 36 weeks of gestation to protect infants from birth up to 6 months of age.

ABRYSVO is a vaccine indicated for active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

Respiratory syncytial virus, also known as RSV, is a virus that can cause an infection in the lungs and airways, producing symptoms that are often similar to a mild cold.

Aug 12, 2024 · Pfizer currently is the only company with an RSV vaccine to help protect older adults, as well as infants through maternal immunization. ABRYSVO is a bivalent vaccine that was designed to provide protection against RSV-LRTD, regardless of the virus subgroup.

Aug 27, 2024 · ABRYSVO received FDA approval in May 2023 for immunization of individuals 60 and older and in August 2023 for immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth up to six months of age

Oct 22, 2024 · Abrysvo now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV immunization approved for pregnant individuals at 32 through 36 weeks of gestation to protect infants from birth up to 6 months of age.

Pfizer’s bivalent RSVpreF vaccine demonstrated significant efficacy against lower respiratory tract disease caused by RSV among older adults over at least 2 seasons. For adults 65 years and older, the majority Work Group opinion was in favor of a universal age-based recommendation.

Sep 19, 2023 · Abrysvo: Pfizer’s RSV vaccine. Pfizer’s trial of 34,284 participants showed that Abrysvo had an 85.7% efficacy in preventing RSV lower respiratory tract disease with three or more symptoms. It dropped to 66.7% when looking at people with just two or more symptoms.

Aug 29, 2024 · Nirsevimab is a monoclonal antibody that prevents severe RSV disease and is recommended for infants and some young children. Pregnant women should get a single dose of the maternal RSV vaccine (Pfizer’s Abrysvo) during weeks 32 through 36 of pregnancy to protect their baby from severe RSV disease.

May 31, 2023 · In Pfizer’s data, the vaccine, called Abrysvo, was 85.7% effective at protecting people against severe RSV—diagnosed as having three or more symptoms of lower respiratory tract...